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PPN1
COGNITIVE FUNCTION IMPAIRMENT IN PATIENTS WITH
NEUROPATHIC PAIN
Povedano M1, Gascón J1, Gálvez R2, Ruíz M3, Rejas J3
1Principes de España Hospital, L´Hospitalet de Llobregat, Barcelona,
Spain; 2Virgen de las Nieves Hospital, Granada, Spain; 3Pﬁzer Spain,
Alcobendas, Madrid, Spain
OBJECTIVE: To analyze the prevalence of cognitive function
impairment (CI) in patients with neuropathic pain (NeP).
METHODS: Cross-sectional analysis of a sample of patients
with NeP enrolled in a naturalistic, multicenter study evaluating
the effectiveness of gabapentin in NeP. A total of 1519 patients
(58.8% women) aged >18 years [mean age (SD) = 56.0 (13.7)
years], with NeP or mixed (neuropathic and nociceptive) pain
(MP) for 1.1 (2.8) years, were enrolled in the study. Pain was
assessed with the McGill sort-form questionnaire, and cognitive
function with the Mini Mental State Examination CMMSE- [a
score °Ü24 was considered as cognitive impairment (CI)]. Mul-
tivariate logistic regression models were used to estimate CI
prevalence. RESULTS: CI was substantially higher in patients
with NeP than that reported in the general Spanish population,
and signiﬁcantly higher than in MP patients: 6.1% (4.0%–8.8%)
versus 1.6% (0.7%–3.1%), p < 0.001 [adjusted OR = 4.36
(1.92–9.92)]. Prevalence signiﬁcantly increased with age up to
28.3% (16.8%–42.4%) in NeP, and to 20.0% (7.7%–38.6%) in
MP for the age groups >75 years, p < 0.001. Patients with periph-
eral diabetic neuropathy and central post-stroke pain had sig-
niﬁcantly higher prevalence than other groups. CI was
signiﬁcantly associated to pain severity in NeP patients. CON-
CLUSIONS: Despite the limitations observed, this evaluation
showed that after adjusting by confounders the prevalence of
cognitive impairment was substantially higher in patients with
NeP as compared to MP and the reference general population.
Age, diabetic neuropathy, and central post-stroke pain were
factors found signiﬁcantly associated to cognitive impairment.
PPN2
THE COST-EFFECTIVENESS OF STRONG, CONTROLLED-
RELEASE OPIOIDS FOR THE TREATMENT OF CHRONIC NON-
MALIGNANT PAIN: A PROBABILISTIC DECISION-MODEL
Hawkins N1, Sculpher M1, Morris J2
1Unversity of York,York, UK; 2Napp Pharmaceuticals, Cambridge, UK
OBJECTIVE: To evaluate the cost-effectiveness of available
treatments for patients requiring a strong, controlled-release
opioid for chronic non-malignant pain. Since patients with
chronic pain typically move between treatment options over
time, according to analgesic response and tolerability, this eval-
uation focuses on the cost-effectiveness of therapeutic sequences.
METHODS: A decision-model was constructed to estimate the
cost-effectiveness of different sequences of controlled-release
(CR) opioids including oxycodone CR, morphine CR, transder-
mal fentanyl and supportive care. Clinical trials involving these
therapies in chronic pain were systematically identiﬁed in the lit-
erature and reported pain scores were mapped across to utilities.
Bayesian meta-analyses were used to compare utilities and
adverse events between therapies. These estimates were then
incorporated within a decision model along with health care cost
estimates, derived using UK prescription data and a survey of
UK GPs. Probabilistic methods were used to address parameter
uncertainty. RESULTS: From a total of 57 published trials, 20
met criteria for inclusion in the meta-analysis. Mean quality-
adjusted life years (QALYs) relative to supportive care were
0.083 for transdermal fentanyl, 0.100 for morphine CR and
0.101 for oxycodone CR. Mean annual health care costs were
estimated at £270 for morphine CR, £854 for transdermal 
fentanyl and £640 for oxycodone CR. The incremental cost-
effectiveness ratio for all therapies, relative to supportive care,
was less than £10,000 per QALY gained (morphine £1800, 
oxycodone 5635, fentanyl £9556) suggesting that, if decision-
makers are willing to pay up to this value, all therapies should
be included in a cost-effective sequence with the most cost-
effective order being morphine CR, oxycodone CR, transdermal
fentanyl and supportive care. CONCLUSIONS: Results of this
analysis indicate that if decision-makers are willing to pay up to
£10,000 per QALY, all three treatments are cost-effective in a
therapeutic sequence. The most cost-effective sequence is mor-
phine CR, oxycodone CR, transdermal fentanyl and supportive
care.
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OBJECTIVE: Neuropathic pain (NeP) results in physical and
psychological burdens for patients, and increased health care
costs. This research compared primary and secondary care
resource utilisation by patients, with and without NeP, in the UK.
METHODS: A large primary care database (DIN-LINK) cover-
ing 100 practices (400GPs) with over 800,000 currently regis-
tered patients representative of the UK population was used. A
cohort of patients who presented to a GP with NeP at any time
during the previous three years was identiﬁed. The comparator
control cohort included patients with no history of NeP matched
by age, sex and GP practice. Patient demographics and resource
utilisation data (prescribed medications, number and length of
prescriptions, GP consultations, out-patient referrals, hospital
admissions, sick notes issued) were reported in total, and for
NeP-related encounters. The follow-up period for each patient
was reported to facilitate comparison. RESULTS: The database
identiﬁed 31,801 patients with NeP. There were similar numbers
of matched control subjects with the same number of follow-up
days. The NeP cohort received 92% more prescriptions in total
during follow-up than those in the matched cohort, and 18% of
prescriptions were NeP related. The NeP cohort had 77% more
GP consultations, (21% were NeP related). Patients with NeP
received 122% more outpatient referrals, (33% were NeP
related. Hospital admissions were up 107% for NeP patients,
(25% were NeP related). Patients with NeP received 186% more
sick notes (52% were NeP related) than those without the con-
dition. CONCLUSION: NeP patients were prescribed more
medications and consumed more primary and secondary care
resources than the matched patient cohort. The fact that addi-
tional resource use was not entirely related to NeP suggests that
differences were not attributable solely to this condition, but may
be due to co-morbidities associated with NeP.
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DIFFERENTIAL COSTS OF NEUROPHATIC PAIN (NEP)
MEDICAL MANAGEMENT ACCORDING TO AETIOLOGY:
RESULTS OF THE REC STUDY
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OBJECTIVE: NeP is managed by a variety of clinicians and
might be caused by broad aetiologies. The economic impact of
medical management is poorly known. The aim of this research
was to estimate the cost of medical management of NeP in Pain
